Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2022 | Post-transplant cyclophosphamide, tacrolimus, and MMF for GvHD in the myeloablative setting

Shernan Holtan, MD, University of Minnesota, Minneapolis, MN, briefly discusses the results of a Phase II study evaluating post-transplant cyclophosphamide, tacrolimus, and mycophenolate mofetil (MMF) for graft-versus-host disease (GvHD) in the myeloablative transplant setting. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Incyte: Research Funding; Vitrac Therapeutics: Research Funding; CSL Behring: Other: Clinical trial adjudication.